Study of Iodine 131 Anti B1 Antibody for 1st or 2nd Relapsed Indolent B-Cell Lymphomas or B-Cell Lymphomas That Have Transformed to a More Aggressive Histology

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 30, 1998

Primary Completion Date

April 30, 2011

Study Completion Date

April 30, 2011

Conditions

Lymphoma, Non-Hodgkin

Interventions

BIOLOGICAL

tositumomab and Iodine I 131 tositumomab (anti-B1 antibody)

For the treatment of 1st or 2nd relapsed indolent B cell lymphomas or B cell lymphomas that have transformed to a more aggressive histology